Eight research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the company’s stock. Get BioCryst Pharmaceuticals alerts:View Our Latest Stock Report on BCRXBioCryst Pharmaceuticals Stock PerformanceNASDAQ BCRX traded up $0.36 on Thursday, hitting $9.43. BioCryst Pharmaceuticals had a negative net margin of 51.71% and a negative return on equity of 76.36%. As a group, research analysts anticipate that BioCryst Pharmaceuticals will post -2.58 earnings per share for the current fiscal year. Further ReadingReceive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.